Analysis charts the emergence and future of advanced therapies DUBLIN, Ohio, May 7, 2025 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) released its 2025 Advanced Therapies Report: Revolutionizing patient care – the promise and potential of cell and gene therapies, providing insights into the evolving landscape of cell and gene therapies (CGTs).Cardinal Health Logo (PRNewsfoto/Cardinal Health) This inaugural report is based on a comprehensive survey of more than 100 healthcare providers as well as interviews with subject matter experts and a patient who received CAR T-cell therapy, all of whom provide valuable insights into the state of the CGT industry. "Cell and gene therapies are poised to revolutionize healthcare treatment for a wide range of diseases," said Craig Cowman, EVP, Biopharma Solutions and Strategic Sourcing at Cardinal Health. "They hold the potential to fundamentally improve the lives of patients with cancer, heart disease, diabetes, and hereditary conditions. Our report provides a comprehensive analysis of the industry's current state and the exciting future that lies ahead." The report underscores the transformative potential of CGTs, particularly for patients with complex and rare conditions, and documents one patient's experiences with CAR T-cell therapy, including the challenges he encountered along the way. The advanced therapy industry is poised for rapid growth, with over 200 therapies projected to be approved and more than 100,000 U.S. patients treated by 2030. Key Report Findings: Challenges to CGT access and adoption persist: Despite the promise of CGTs, there are significant obstacles, including referral processes, high costs, complex logistics and reimbursement uncertainties. 56% of survey respondents stated that financial constraints, such as high acquisition costs, are a barrier. 54% said that lack of or inadequate reimbursement is a challenge. Collaboration is key to overcoming challenges to access: There is a critical need for improved collaboration across all industry stakeholders, including manufacturers, payers, providers and patients. 69% of survey respondents said that strategic initiatives between payers and manufacturers, such as innovative payment models, are needed for increased access. 53% stated that extending facilities beyond academic/medical center hubs is important to improving access to CGTs. Many patients still do not receive the CGT treatments they need: 64% of survey respondents cited insufficient social support (e.g., lack of care partner availability, etc.) as the most common reason. 57% cited prior authorization denial as another significant reason. Story Continues "In many ways, we're still in the very early stages of the incredibly promising CGT industry," said Fran Gregory, Vice President of Emerging Therapies at Cardinal Health. "However, it is also time to take stock of where we stand currently and discuss ideas to help us navigate the significant changes that the growth of these therapies is bringing. Our new report shows how we can move the industry forward." The report can be accessed here. About Cardinal Health Cardinal Health is a distributor of pharmaceuticals and specialty products; a global manufacturer and distributor of medical and laboratory products; a supplier of home-health and direct-to-patient products and services; an operator of nuclear pharmacies and manufacturing facilities; and a provider of performance and data solutions. Our company's customer-centric focus drives continuous improvement and leads to innovative solutions that improve people's lives every day. Learn more about Cardinal Health at cardinalhealth.com and in our Newsroom. Contacts Media: Kelli Nowinsky, [email protected] and 614-205-3073 Investors: Matt Sims, [email protected] and 614.553.3661Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cardinal-health-releases-new-report-on-the-cell-and-gene-therapy-industry-302447744.html SOURCE Cardinal Health View Comments
Cardinal Health releases new report on the cell and gene therapy industry
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...